Navigation Links
Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,,,Tissue

overnight at 37C. (We place the slides and a moist paper towel in a sealed plastic container in an incubator.) The next day, slides are washed by immersion in PBS for 5 minutes and dehydrated in graded ethanols as described.

Reverse transcription. RNA is reverse transcribed to cDNA in a 40l mixture containing 20 mM Tris-HCL (ph 8.4), 50 mM KCl, 2.5 mM MgCl2, 0.2 mM of each deoxynucleotide triphosphate (dNTP), 100 ng of selected reverse primer (we use 20 mers) and 2 U of reverse transcriptase at 42C for 45 minutes in a humidified chamber. Following reverse transcription, the slides are washed by immersion in PBS and dehydrated in graded ethanols as described.

PCR amplification. PCR amplification is performed in a 100l mixture containing 20 mM Trishcl (ph 8.3), 50 mM kcl, 1.5 mM MgCl2, 0.001% gelatin, 0.2 mM dntps, 15% glycerol and 100 ng of each primer. Primers should be designed to yield a product less than 300 bp in size, and we use the same reverse primer as used for reverse transcription. This reaction mixture is applied to each tissue slice and covered using the resealable GeneFrame product. Amplification is then performed using the in situ adapter for the RoboCycler 40 Temperature Cycler. The following conditions are used: 96C for 2 minutes, 40 cycles at 96C for 30 seconds, 52C for 30 seconds, 74C for 60 seconds and one cycle at 74C for 5 minutes. After cycling, the slices are washed by immersion for 5 minutes in PBS and then dehydrated in graded ethanols as described.

Hybridization. The probe is readily generated by PCR using digoxigeninlabeled primers. In situ PCR amplification products are then detected by hybridization to digoxigeninlabeled DNA probes9 in hybridization buffer (2x SSC, 50% formamide, 7.5% dextran sulfate and 100 to 200 ng of probe). The hybridization solution is added to the slices moun
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells
2. Two-dimensional Optimization of a Semi-nested PCR for Detecting Listeria monocytogenes
3. Detecting miRNA & siRNA
4. Detecting Attomole Amounts of Small RNA
5. Structural Analysis of Glycosylated Peptides in Complex Mixtures with Ion Trap MSn
6. Efficient Primary Structure Elucidation of Disulfide-bridged Peptides
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
9. Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer
10. Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80
11. LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures
Post Your Comments:
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...wing a devastating legal rebuke, the chief executi... to pursue other business interests. , ,Jeff Cason...provider of uninterruptible power supply services,...es. Former executive vice president Charley Eaton ...was sued for copyright infringement by UPS manufac...
...part of a new contract with General Motors , the ...ill design plug-in batteries for a Saturn hybrid...hnson Controls-Saft Advanced Power Solutions will... recharged from a typical household electrical out...n recent months for JCS. In August of 2006, the Eu...
... a Wisconsin entrepreneur what,s vital to the succ...o get a shopping list as a definitive answer. Find...lth insurance, protecting intellectual property, a...replies. , ,Holding down taxes? That,s on the shor...er depends on the entrepreneur. Those who aren,t y...
Other Biology Technology:High taxes and low rates of entrepreneurship - is there a relationship? 2High taxes and low rates of entrepreneurship - is there a relationship? 3
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 1Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 3Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 4Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 5Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 6Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 7Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 8Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 9CareFusion Form 10 Registration Statement Declared Effective 52998 1CareFusion Form 10 Registration Statement Declared Effective 52998 2CareFusion Form 10 Registration Statement Declared Effective 52998 3CareFusion Form 10 Registration Statement Declared Effective 52998 4Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 1Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 2
...hange(TM) Software Access Local ...g. 13 BIO-key International,Inc. (OTC Bulletin Bo...utions and finger based biometric identification, ...ftware Module and its acceptance by several,agenci...This contract,represents BIO-key,s first with the ...
...on,Intelligence Corporation (OTC Bulletin Board: C...of electronic signature solutions for,business pro...recognized,leader in biometric signature verificat... three and six-month periods ended June 30, 2007. ...iod ended June 30,2007 increased 24% compared to $...
...o Equity, JERICHO, N.Y., Aug. 15 bioMETRX, Inc. ...d supplier of consumer,biometric products, today a... holders of its Series B common stock warrants tha... company by August 25, 2007. The Company notified...t,has elected to pay such holders $0.12 per share,...
Other Biology News:BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 2Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 4Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 5bioMETRX, Inc. Calls Series B Warrants 2
...Description: Proteinase K is a highly active and s...ations purified from the fungus T. album. It cleav...up of N-substituted hydrophobic aliphatic and arom...e protease. Proteinase K is useful in purifying hi...
..., high throughput, water bath thermal cycler capab...oplates. This equates to 9,216 reactions per run w...y transfers a basket of plates between three water... are considerably faster than those of peltier blo...
...tidine Dideoxycytidine is a cytidine analog that ...viral activity. Immunogen: Chemical / Small Mol...ficity of the ddC antiserum was determined by calc...ddC analog at the 50% intercept of the respective ...
MSC.12 class II safety cabinet (Type A1) - CE Marked (230V / 50Hz) from Thermo Scientific
Biology Products: